SAMEER ARAIN: Open Payments
NPI 1750305546 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,838 in 100 payments from 12 companies in 2025. Trend: 2023 $485 · 2024 $512 · 2025 $1,838
Food & beverage: $1,831Education: $8
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 46 | $557 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $309 |
| Axsome Therapeutics, Inc. | 4 | $261 |
| Alkermes, Inc. | 5 | $220 |
| Otsuka America Pharmaceutical, Inc. | 12 | $199 |
| Teva Pharmaceuticals USA, Inc. | 5 | $81 |
| Vanda Pharmaceuticals Inc. | 4 | $69 |
| Neurocrine BioSciences, Inc. | 3 | $54 |
| Janssen Pharmaceuticals, Inc | 2 | $33 |
| Luye Pharma (USA) Ltd. | 1 | $23 |
Products named: COBENFY, CAPLYTA, Auvelity, REXULTI, LYBALVI, UZEDY, FANAPT, ABILIFY MAINTENA.
Industry payments across MO — which companies pay providers there.
